The IMID Forum
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
Filtered episodes(1)
- StandardSummaries onlyDiscussing PsA: Risankizumab efficacy across machine learning defined and complex PsA phenotypes
Published Feb 13, 2026
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘classification of patients into distinct PsA phenotypes based on baseline demographics and clinical characteristics using a machine learning approach, and consensus-derived GRAPPA terminology, to support shared clinical decision making, and enable more effective patient stratification in both observational studies and clinical trials.